Elevance Health Inc. closed $174.10 below its 52-week high ($567.26), which the company achieved on September 3rd.

Barclays raised the firm’s price target on Elevance Health (ELV) to $512 from $501 and keeps an Overweight rating on the shares post the Q4 ...

The stock has lagged behind the Dow over the longer term as well. ELV stock has declined 16.7% on a YTD basis and 18.5% over the past 52 weeks compared to DOWI’s 18.8% gains in 2024 and 23.9% ...

US stocks showed mixed signals in premarket trading on Thursday. Futures for the S&P 500 lost 0.1% before the opening bell, ...

Stocks closed solidly higher on Thursday for the fourth straight session as investor optimism about the Trump administration continues to run high.

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Elevance Health (ELV – Research Report), with a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Dow Jones Industrial Average (DJIA) is slipping today despite investors preparing for the upcoming Federal Reserve meeting. Traders have been waiting for this meeting as it will be a major ...

Shares of Elevance Health Inc. ELV shed 0.61% ... with the S&P 500 Index SPX falling 1.07% to 5,906.94 and Dow Jones Industrial Average DJIA falling 0.97% to 42,573.73. This was the stock's ...